Skip to content
PubMed This is a summary of 57 peer-reviewed journal articles Updated
Endocrinology

CIDEC-related familial partial lipodystrophy: A Patient Guide

At a Glance

CIDEC-related familial partial lipodystrophy (FPLD5) is a rare genetic disorder that changes fat storage, causing fat loss in the limbs and buttocks and fat buildup in the trunk or organs. Insulin resistance can lead to diabetes, high triglycerides, and fatty liver disease, but complications can be managed.

CIDEC-related familial partial lipodystrophy, also known as FPLD5, is a very rare genetic condition that changes how your body stores and manages energy. Because FPLD5 is so rare, individual features can vary significantly from person to person, and this guide does not replace a clinician’s individualized care plan.

At its core, this is a disorder of the fat cells, or adipocytes. In a healthy body, these cells act as storage tanks for fat, keeping it safely tucked away until the body needs it for fuel. In people with FPLD5, a mutation in the CIDEC gene disrupts the specialized machinery required to build these storage tanks, which can lead to a cascade of metabolic challenges [1].

The biological mechanism behind FPLD5 involves a failure of lipid droplet fusion. Normally, the CIDEC protein allows tiny droplets of fat within a cell to merge into one large, stable droplet [2]. Without a functional CIDEC protein, the fat remains fragmented into many tiny droplets that the cell cannot manage effectively. Because these cells can no longer provide safe storage, the body may lose fat in certain areas—most notably from the arms, legs, and buttocks—while compensating by storing fat in the face, neck, and trunk [1].

When the natural storage areas under the skin fail, the fat may be redirected into organs that were never meant to hold it, such as the liver and skeletal muscles. This redistribution, known as ectopic fat storage, can trigger severe insulin resistance. This resistance is a major driver behind the condition’s primary medical complications: type 2 diabetes, elevated levels of blood fats (hypertriglyceridemia), and fatty liver disease [1][3]. Not every person develops every listed problem, and severity varies.

While living with such a rare condition can be daunting, a diagnosis of FPLD5 provides a framework for your care. Although there is currently no cure for the underlying genetic mutation, the metabolic complications can be treated through a dedicated, coordinated approach. By working with your clinical team to focus on tailored nutrition and targeted medications, you can manage your risks and work to protect your long-term health [4].

Common questions in this guide

What is CIDEC-related familial partial lipodystrophy (FPLD5)?
It is a very rare inherited disorder in which a CIDEC gene mutation changes how fat cells store energy. People may lose fat from the arms, legs, and buttocks while storing more fat in the face, neck, trunk, or internal organs.
Why does FPLD5 cause fat loss in some areas and fat gain in others?
The CIDEC protein normally helps small fat droplets join into a stable storage droplet inside fat cells. When CIDEC does not work properly, fat storage becomes fragmented, so fat can be lost from under the skin and redirected to areas such as the trunk, liver, and muscles.
What health complications can FPLD5 cause?
Abnormal fat distribution can lead to insulin resistance, which means the body has trouble responding to insulin. This can contribute to type 2 diabetes, high triglyceride levels, and fatty liver disease, although not everyone develops every complication.
Can CIDEC-related familial partial lipodystrophy be cured?
There is currently no cure for the underlying CIDEC gene mutation. However, tailored nutrition, lifestyle changes, and medications can help manage metabolic complications and protect long-term health.
Why can someone with FPLD5 look lean but still have metabolic problems?
FPLD5 can reduce the amount of fat stored under the skin in the limbs and buttocks while sending more fat to the trunk or organs. This internal fat storage can cause insulin resistance even when a person appears lean in some areas.
How should people with FPLD5 be monitored?
Care is coordinated by a clinical team that follows metabolic health and watches for fat accumulation in organs such as the liver and muscles. Ask your team how often you need assessments for blood sugar, blood fats, liver health, and other risks based on your individual situation.

Get notified when new evidence is published on CIDEC-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (4)
  1. 1

    Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

    Patni N, Xing C, Huang CY, et al.

    International journal of molecular sciences 2026; (27(2)) doi:10.3390/ijms27020646.

    PMID: 41596298
  2. 2

    Human CIDEC transgene improves lipid metabolism and protects against high-fat diet-induced glucose intolerance in mice.

    Gupta A, Balakrishnan B, Karki S, et al.

    The Journal of biological chemistry 2022; (298(9)):102347 doi:10.1016/j.jbc.2022.102347.

    PMID: 35963433
  3. 3

    When Adipose Tissue Lets You Down: Understanding the Functions of Genes Disrupted in Lipodystrophy.

    Rochford JJ

    Diabetes 2022; (71(4)):589-598 doi:10.2337/dbi21-0006.

    PMID: 35316838
  4. 4

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244

This page is for informational purposes only and does not constitute medical advice or replace an individualized care plan. An endocrinology or genetics team can help interpret your FPLD5 risks and guide treatment.